ADC Therapeutics SA (ADCT)

NYSE: ADCT · IEX Real-Time Price · USD

1.66

+0.07 (4.40%)

Dec 29, 2023, 4:00 PM EST - Market closed

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018
Revenue	209.91	33.92	0	2.34	1.14
Revenue Growth (YoY)	518.89%	-	-	105.26%	-
Cost of Revenue	4.58	1.39	0	0	0
Gross Profit	205.33	32.52	0	2.34	1.14
Selling, General & Admin	141.06	136.24	77.23	14.2	8.77
Research & Development	187.9	158	142.03	107.54	118.31
Operating Expenses	328.96	294.24	219.26	121.74	127.08
Operating Income	-123.63	-261.72	-219.26	-119.4	-125.94
Interest Expense / Income	36.92	18.34	4.93	0.16	0
Other Expense / Income	-5.89	-28.56	21.77	-3.65	-3.07
Pretax Income	-154.66	-251.51	-245.96	-115.9	-122.87
Income Tax	1.14	-21.48	0.33	0.58	0.22
Net Income	-155.8	-230.03	-246.29	-116.48	-123.1
Shares Outstanding (Basic)	78	77	71	67	-
Shares Change	2.13%	8.21%	6.04%	-	-
EPS (Basic)	-1.99	-3.00	-3.77	-2.36	-2.64
EPS (Diluted)	-1.99	-3.00	-3.77	-2.36	-2.64
Free Cash Flow	-104.67	-230.93	-168.85	-122.8	-123.17
Free Cash Flow Per Share	-1.34	-3.01	-2.38	-1.84	-
Gross Margin	97.82%	95.89%	-	100.00%	100.00%
Operating Margin	-58.90%	-771.65%	-	-5102.52%	-11047.46%
Profit Margin	-74.22%	-678.20%	-	-4977.95%	-10797.89%
Free Cash Flow Margin	-49.86%	-680.85%	-	-5247.74%	-10804.56%
EBITDA	-115.41	-230.54	-239.07	-114.1	-122.13
EBITDA Margin	-54.98%	-679.70%	-	-4876.07%	-10713.33%
Depreciation & Amortization	2.33	2.63	1.97	1.65	0.74
EBIT	-117.74	-233.17	-241.04	-115.75	-122.87
EBIT Margin	-56.09%	-687.46%	-	-4946.41%	-10778.25%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).